Genmab — August 2025
-
Genmab Announces Phase 3 EPCORE
FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) https://proinvestor.com/investornyt/1348495/genmab-announces-phase-3-epcore-fl-1-clinical-trial-met-dual-primary-endpoints-in-patients-with-relapsed-refractory-r-r-follicular-lymphoma-fl -
Underligt hemmelig-ish X-twit fra Gmab. The @US_FDA has accepted for priority review, the application for one of our products for consideration as a treatment for adults with relapsed/refractory follicular #lymphoma who have received at least one prior therapy.
-
Guidance/Opdaterede Forventninger: Genmab har opjusteret sine forventninger til hele 2025. Den reviderede guidance for omsætning er nu $3.500 - $3.700 mio. (tidligere $3.340 - $3.660 mio.), og for driftsresultat er den nu $1.055 - $1.405 mio. (tidligere $895 - $1.365 mio.).
-
Genmab Announces Financial Results for the First Half of 2025 https://proinvestor.com/investornyt/1348524/genmab-announces-financial-results-for-the-first-half-of-2025
-
ADS stiger umiddelbart med 5,67% - lad os se....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind